1.Name of the securities:common stocks of Elixiron Immunotherapeutics
Cayman) Limited
2.Trading date:2026/03/11~2027/06/30
3.Date of the board of directors resolution:NA
4.Other approval date:2026/08/21
5.Amount, unit price, and total monetary amount of the transaction:
Amount: 2,700,000 shares have been disposed of and an additional
1,000,000 shares are expected to be disposed of in the future.
Unit price: The average disposal price of the shares already disposed of
was approximately NTD 77.92 per share (before deduction of applicable
taxes and transaction costs). The disposal price of the remaining shares
will be no less than NTD 95 per share and will be announced separately
upon completion of the disposal.
Total monetary amount of the transaction: NTD 210,373,700 for the shares
already disposed of (before deduction of applicable taxes and
transaction costs). The amount relating to future disposals will be
announced separately upon completion of the disposal.
6.Gain (or loss) through disposal (not applicable in case of acquisition of
securities):
Gain from the shares already disposed of amounted to NTD 154,008,019.
The gain or loss from future disposals will be announced separately upon
completion of the disposal.
7.Relationship with the underlying company of the trade:
It is not a related party.
8.Current cumulative amount held, monetary amount, and shareholding
percentage of cumulative holdings of the securities being traded (including
the current trade), and status of any restriction of rights (e.g.pledges):
Cumulative volume: 3,538,819 shares
Cumulative amount: NTD 72,942,361
Shareholding percentage: 2.64%
Status of any restriction of rights: None
9.Current ratio of securities investment (including the current trade, as
listed in article 3 of Regulations Governing the Acquisition and Disposal of
Assets by Public Companies) to the total assets and equity attributable to
owners of the parent as shown in the most recent financial statement and
working capital as shown in the most recent financial statement as of the
present:
Current ratio of securities investment to the total assets : 1.88%
Current ratio of securities investment to the equity attributable to
owners of the parent: 2.25%
Working capital as shown in the most recent financial statement:N/A
10.Concrete purpose of the acquisition or disposal:
For the needs of adjusting portfolio composition
11.Any dissenting opinions of directors to the present transaction:N/A
12.Whether the counterparty of the current transaction is a related party:No
13.Trading counterparty and its relationship with the Company:N/A
14.Date of ratification by supervisors or approval by
the audit committee:NA
15.Date on which material information regarding the same event
has been previously released:NA
16.Any other matters that need to be specified:
Approval was granted on March 11, 2026, for the disposal of 2,700,000
shares, which have been fully disposed of. A subsequent approval was
obtained on August 21, 2026, for the disposal of an additional
1,000,000 shares.